In ALL, AKT but not ERK1/2 affects in vitro NF-κB signaling by CCN1 (Zhu et al. 2016), whereas in CML, AKT nor ERK1/2 are involved in in vitro NF-κB signaling by CCN1 (Song et al. 2019). The gene discussed is MAPK3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.